Abstract
This review looks at the challenges facing the worldwide community with the increasing problem of methicillin resistance in Staphylococcus aureus. The epidemiology and natural history of community-associated methicillin-resistant Staphylococcus aureus and the challenge of control is discussed. Options for treatment and review of key antimicrobial agents acting against methicillin-resistant S. aureus, both currently in use and in development, are addressed. There are a number of new agents, the place of which in therapeutic regimens is yet to emerge. The review attempts to inform the reader of the probable position of these agents.
| Original language | English |
|---|---|
| Pages (from-to) | 601-18 |
| Number of pages | 18 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 6 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Oct 2008 |
Keywords
- iclaprim
- tigecycline
- linezolid
- ceftobiprole
- quinupristin-dalfopristin
- dalbavancin
- telavancin
- ceftaroline
- methicillin-resistant S. aureus treatment
- daptomycin
- tomopenem
- community-associated methicillin-resistant Staphylococcus aureus
- oritavancin
Fingerprint
Dive into the research topics of 'Current challenges in treating MRSA: what are the options?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver